MELVILLE, N.Y., July 13, 2016 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BRT" or the “Company") (OTCBB:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Ed Field, the Company’s President of the Disc/Spine Division, is presenting at the 3rd Annual Regenerative Medicine Essentials Course, held by the Wake Forest Institute for Regenerative Medicine in Winston Salem, NC. On Friday, July 15th, Mr. Field will deliver his presentation entitled, "Getting to Market: Interactive case studies with discussions on clinical trial plans, regulatory pathways and funding options,” which will include a case study on the development of the Company’s therapy for the treatment of chronic lumbar disc disease.
The primary objective of the Regenerative Medicine Essentials Course is to provide a various state-of-the-art review of the various aspects of regenerative medicine including background material, the key scientific component of the field of regenerative medicine, ethical, economic and other issues important to regenerative medicine. This one-week course, taught by prominent experts, provides attendees a foundation in the next evolution of modern health care.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.